If a protocol violation is discovered after data analysis, which steps should be taken?

Enhance your knowledge of clinical trial principles with our ACRP GCP and Clinical Trial Principles Test. Utilize flashcards and multiple choice questions, complete with detailed explanations, to elevate your preparation and excel in your exam!

Multiple Choice

If a protocol violation is discovered after data analysis, which steps should be taken?

Explanation:
When a protocol violation is found after data analysis, the proper approach is to document the violation, assess its impact on data integrity and participant safety, notify the sponsor and the IRB/ethics committee, and implement corrective actions to prevent recurrence. Documenting provides an auditable record of what happened and why. Assessing impact helps determine whether the violation could have biased results, affected safety or informed consent, or altered the validity of conclusions, guiding whether re-analysis, re-consent, or other study modifications are needed. Notifying the sponsor and IRB ensures appropriate oversight and decisions about further actions, approvals, or whether any study changes are required. Implementing corrective actions closes the loop by addressing root causes and reducing the risk of recurrence. Re-running analyses without altering data would not address the violation and could misrepresent the integrity of the study. Delaying reporting until the next data cut postpones necessary oversight, and erasing data to re-run the study destroys the original record and undermines regulatory and ethical standards.

When a protocol violation is found after data analysis, the proper approach is to document the violation, assess its impact on data integrity and participant safety, notify the sponsor and the IRB/ethics committee, and implement corrective actions to prevent recurrence. Documenting provides an auditable record of what happened and why. Assessing impact helps determine whether the violation could have biased results, affected safety or informed consent, or altered the validity of conclusions, guiding whether re-analysis, re-consent, or other study modifications are needed. Notifying the sponsor and IRB ensures appropriate oversight and decisions about further actions, approvals, or whether any study changes are required. Implementing corrective actions closes the loop by addressing root causes and reducing the risk of recurrence.

Re-running analyses without altering data would not address the violation and could misrepresent the integrity of the study. Delaying reporting until the next data cut postpones necessary oversight, and erasing data to re-run the study destroys the original record and undermines regulatory and ethical standards.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy